Izotropic Corp. · CSE:IZO
Izotropic — Investor Presentation (September 2021)
22 slides from Izotropic's investor presentation, September 2021
Slide 1: Izotropic Corporation Investor Presentation
&)) IZOTROPIC Weagu! CORPORATION INVESTOR PRESENTATION Gizoview
Slide 2: Izotropic Corporation
IZOTROPIC CORPORATION The only publicly traded company commercializing a dedicated breast CT im for the more accurate detection and diagnosis of breast cancers. BREAST CT EVOLUTION * $20M spent on R&D to date ¢ Performing prototypes and ongoing clinical trials ¢ Published journal articles ¢ Propriet
Slide 3: Licensed Technology & Intellectual Property
LICENSED TECHNOLOGY & INTELLECTUAL PROPERTY GLOBAL LICENSING RIGHTS * Exclusive worldwide licensing rights to Breast CT through an agreement with The Regents of The University of California * Developed over 20 years by principal technology founder and company director Dr. John M. Boone * Commerciali
Slide 4: True 3D Breast CT Imaging
; \ 4\ eet TRUE 3D BREAST CT IMAGING S To expedite patient and provider access to |zoView, the initial clinical study will demonstrate superior performance of diagnostic breast CT imaging over diagnostic mammography procedures and will initiate in Q2 2022. Platform applications will be validated in
Slide 5: Breast Cancer Is Now the Most Common Form
4 BREAST CANCER IS NOW THE MOST COMMON FORM U.S. Breast Cancer Landscape Facts. 41M BREASTS SCANS IN 2019 280K NEW BREAST CANCER CASES * Screening mammography misses 1/5 cancers = 1 in 8 women will be diagnosed with breast * 9,000 imaging centers and >20,000 cancer in their lifetime, 1 in 39 will di
Slide 6: Diagnostic Mammography Challenges
DIAGNOSTIC MAMMOGRAPHY CHALLENGES ‘ay CONTINUAL BREAST COMPRESSION * Technician manipulation of the breast for multiple imaging views * 46% of patient non-compliance is due to pain * Concerns with breast implants (ie. discomfort and rupture) REQUIRES TECHNICAL SKILL AND LONG WORK FLOW © Up to 12 ind
Slide 7: IzoView Breast CT
&,, IZOVIEW BREAST CT i) A whole new experience for patients, radiologists and providers. Gizoview Lr For illustrative purposes only. Not yet approved for sale CSE: 1ZO OTCQB: IZOZF NO BREAST COMPRESSION ¢ Natural breast orientation preserved, no pain or discomfort, very comfortable face down view,
Slide 8: Solving an Unmet Need
SOLVING AN UNMET NEED Mee Images below are of the same breast. Mammography Tomosynthesis Wy 2D Image 2.5D Image
Slide 9: IzoView Platform Uses
IZOVIEW PLATFORM USES Making Breast CT an indispensable tool for improving the outcomes of br STEPS TO TREATMENT: PLATFORM PRODUCTS: SALES MODELS: CSE: IZO OTCQB: IZOZF SCREENING DIAGNOSTIC BIOPSY TREATMENT NEWINDICATIONS INITIAL REGULATORY NEW ACCESSORIES NEW DEVIC! FOCUS o—————_o ONE TIME, RENTAL,
Slide 10: Market Acceptance
MARKET ACCEPTANCE ei) PATIENTS Breast CT can create a better experience for wider patient adoption Customers are asking for IZOVIEW today. DOCTORS 3D visualization capabilities and the use of contrast expands use cases HOSPITALS & CLINICS Can improve throughput and attract more patients INSURANCE PA
Slide 11: Commercial Development Pathway
Zi COMMERCIAL DEVELOPMENT PATHWAY Yay PROOF OF RESEARCH & ACADEMIC READY TO CONCEPT PROTOTYPES CLINICAL TRIALS COMMERCIALIZE COMMERCIAL COMMERCIAL CLINICAL CLINICAL REGULATORY DESIGN (CURRENT) PROTOTYPE DEVICE STUDY SUBMISSION lan WY © Design final device and « Hardware and software * Complete izovi
Slide 12: Timelines
TIMELINES Q3 + Implementation of 3D imaging reconstruction software begins + Mechanical and electrical design completed * Clinical trial design finalized CSE: 1ZO OTCQB: IZOZF Q4 + Industrial design completed + Fabrication of Izoview begins for the initial device build * Clinical trial site selectio
Slide 13: Broad Engagement Preparing for Market
BROAD ENGAGEMENT PREPARING FOR MARKET Near-term catalysts across multiple workstreams. DEVELOPMENT REIMBURSEMENT ¢ Al software modules and hardware + Expanding payor engagement accessories to expand izoview platform * Collaborating with payors on ¢ Partnerships to accelerate product secondary clinic
Slide 14: Directors & Management
DIRECTORS & MANAGEMENT a JOHN MCGRAW, PHD JOHN M. BOONE, PHD YOUNES ACHKIRE, PHD BOB THAST CEO Founder & Director EVP Product Engineering Director & Special Advisor Executive in imaging, diagnostic Medical Physicist, Professor, Medical device R&D expert, managing Capital markets specialist, service,
Slide 15: Dr. John Boone
DR. JOHN BOONE Principal Founder of Breast CT Technology & Director "We scanned the first patient using cone beam breast CT in 2004, scanned the first cancer patient in early 2005, and performed the first contrast - enhanced breast CT exam in 2006. | take my cues from the breast imaging radiologists
Slide 16: Dr. John McGraw
EZ, ou DR. JOHN MCGRAW Chief Executive Officer "High resolution breast imaging is critical to identifying * Senior VP of Business Development & malignancies as early as possible. Izotropic's Breast CT Strategy, CML Healthcare (TSX: CLC) Canada's has the opportunity to offer patients, with or without
Slide 17: Dr. Younes Achkire
DR. YOUNES ACHKIRE Executive Vice President of Product Engineering "As a medtech engineering executive with decades of experience, | know the potential Izoview has to disrupt the world of breast imaging. With my expertise in developing high precision equipment, | will engineer novelties in Izoview t
Slide 18: Medical & Scientific Advisors
MEDICAL & SCIENTIFIC ADVISORS f Internationally Recognized Specialists that played vital roles in establishing curr DR. MARTIN YAFFE DR. KAREN LINDFORS DR. NORBERT PELC PHD MD, MPH, FACR DSc Work is focused on improving Drove the development of Expert in the field of breast . E Y i Founder of 3 biot
Slide 19: Market Capitalization
MARKET CAPITALIZATION September 3, 2021 52 WEEK RANGE - CSE: CAD $0.2400 - 1.5600 52 WEEK RANGE - OTC: US $0.5720 - $1.3100 52 WEEK RANGE - FSE: EUR $0.1530 - $1.0200 COMMON SHARES ISSUED - BASIC: 942,546,078 WARRANTS: 6,050,000 @ $0.20 WARRANTS: 6,407,400 @ $0.75 WARRANTS: 1,896,679 @ $1.50 BROKER
Slide 20: Legal
LEGAL SECURITIES COUNSEL; CLARK WILSON LLP https://www.cwilson.com: TRUST AGENT: ODYSSEY TRUST https://odysseytrust.com U.S. PATENT COUNSEL: VENABLE LLP https://www.venable.com REGULATORY COUNSEL: BROOKE CONSULTING LLC https://www.brooke-consulting.com CSE: 1ZO OTCQB: IZOZF BREAST CT IMAGING - 20
Slide 21: Disclaimer
DISCLAIMER This document may contain statements that are “Forward-Looking Statements,” which are based upon the current estimates, assumptions, projections and expectations of the company’s management, business, and its knowledge of the relevant market and economic environment in which it operates.
Slide 22: Investor Relations
INVESTOR RELATIONS: IR@izocorp.com 1-833-IZOCORP James Berrard ext.1 Tyler Muir ext.2 GENERAL INQUIRIES info@izocorp.com izocorp.com 1-833-IZOCORP ext. 3 W eeizotroric Eeizorroric ff e@izotrRoeIc CSE: 1ZO OTCQB: IZOZF BREAST CT IMAGING - 22